AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On May 15, 2025, Capricor's stock experienced a significant drop of 10.04% in pre-market trading, reflecting investor concerns and market sentiment.
Capricor Therapeutics reported a widening net loss for the first quarter of 2025, primarily due to increased research and development expenses and strategic investments in manufacturing and clinical operations. The company's earnings per share (EPS) of -$0.53 missed analyst expectations of -$0.32, further contributing to the negative market reaction. Additionally, revenue for the quarter was reported at $0, a stark decline from $4.9 million in the same period last year.
Despite the challenging financial results,
Fitzgerald maintained a buy rating on , indicating confidence in the company's long-term prospects. This rating suggests that the current market downturn may present a buying opportunity for investors who believe in the company's innovative pipeline and strategic investments.
Knowing stock market today at a glance

Dec.19 2025

Dec.19 2025

Dec.19 2025

Dec.19 2025

Dec.19 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet